You are here

ULTRAFÎLTRASYONUN DÎGÎTAL BENZERÎ ÎMMÜNREAKTÎF MADDE (DLIS), ATRIAL NATRÎÜRETÎK PEPTÎD (ANP) VE EKOKARDÎYOGRAFÎK PARAMETRELER ÜZERÎNDEKÎ ETKÎSÎ

THE EFFECTS OF ULTRAFILTRATION ON DIGITALIS-LIKE IMMUNOREACTIVE SUBSTANCE (DLIS), ATRIAL NATRIURETIC PEPTIDE (ANP) AND ECHOCARDIOGRAPHY PARAMETERS

Journal Name:

Publication Year:

Abstract (2. Language): 
Assessment of dry weight in hemodialysis patients is essential. Intravascular hypervolemia increases the levels of digitalis-like immunoreactive substance (DLIS), atrial natriuretic peptide (ANP) and it alters echocardiographic parameters. The basal levels of DLIS in forty-two hemodialysis patients were significantly higher when compared with control (n:20) (p< 0.05). Since endogenous DLIS gives cross-reaction to anti-digoxin antibodies, the levels of DLIS were determined by two seperate techniques, FPIA (fluorescence polarization enzyme immunoassay) and MEIA (microparticle enzyme immunoassay). The strong positive correlation between DLIS-FPIA andDLIS-MEIA (r:0.894, p<0.001) made us think that these two markers could be used interchangeably. Compared to the corresponding parameters of forty-two hemodialysis patients, DLIS and ANP levels and diameters ofright and left atria of eleven patients, selected as hypervolemic by conventional criteriae, were higher. After three months of ultrafiltration treatment, we determined that the levels of DLIS, ANP and diameters of both atria decreased significantly approaching control levels. We concluded that the tests of DLIS and ANP combined with atrial echocardiographic parameters were useful to determine the intravascular volume response to ultrafiltration treatment
Abstract (Original Language): 
Hemodiyaliz hastalarında kuru ağırlığın hatasız olarak ölçülmesi yaşamsal önem taşımaktadır. İntravasküler hipervolemi digital benzeri immünreaktif madde (digitalis¬like immunoreactive substance:DLIS) ve atriyal natriüretik peptid (ANP) düzeylerini arttırmakta ve ekokardiyograflk parametreleri etkilemektedir. İncelemeye alınan 42 hemodiyaliz hastasının bazal DLIS düzeyleri kontrol grubundan (n:20) daha yüksek bulunmuştur (p<0.05). Endojen DLLS'in anti-digoksin antikorları ile verdiği çapraz reaksiyon nedeniyle, DLIS düzeyleri FPIA (floresan polarizasyon enzim immünassay) ve MEIA (mikropartikül enzim immünassay) yöntemleriyle belirlenmiştir. DLIS-FPIA ve DLIS-MEIA arasındaki kuvvetli pozitif korelasyon (r:0.894,p<0.001), bu iki testin birbiri yerine kullanılabileceğini düşündürmüştür. Tüm hemodiyaliz hastaları içinden konvansiyonel kriterlere göre hipervolemik olduğu saptanan 11 hastanın DLIS ve ANP düzeyleri, sağ ve sol atrium çapları genel diyaliz populasyonunun benzer parametrelerinden daha yüksek bulunmuştur. Üç aylık ultrafıltrasyon işleminin sonunda DLIS,ANP düzeyleri ile sağ ve sol atriyum çapları anlamlı olarak gerilemiştir. DLIS ve ANP ölçümlerinin, atrial ekokardiyograflk parametreler ile birlikte , ultrafıltrasyona alınan yanıtın değerlendirilmesinde tanısal değere sahip olduğu sonucuna varılmıştır
FULL TEXT (PDF): 
8-14

REFERENCES

References: 

1.
Akçiçe
k F, Dorhout Mees EJ . Kuru ağırlık kavramı. Akoğlu E (ed). Hemodiyaliz El Kitabı. Türk Nefroloji Derneği Yayınları, Îstanbul, 1995:38-44.
2. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J
Physiol 1984 ; 247: F632-F636.
3. Cheriex EC, Leunissen KML, Janssen JH, Mooy JM, vanHoof JP. Echography of the inferior vena cava is a simple and reliable tool for estimation of dry weight in hemodialysis patients. Nephrol Dial Transplant 1989 ; 4:563-568.
4. Leunissen KML, Kouw P, Kooman JP, Cheriex EC, De Vries PMJM, Donker AJM, vanHoof JP. New techniques to determine fluid status in hemodialysed
patients. Kidney Int 1993 ; 43:550-556.
5. Don C, Burns KD, Levine DZ . Body fluid volume status in hemodialysed patients: the value of the chest
radiograph. Can Assoc Radiol J 1990 ; 41:123-126.
6. Guyton AC . Renal function curve : a key to understanding the pathogenesis of hypertension.
Hypertension 1987 ; 10:1-6.
7. Compty CM, Shapiro FL . Cardiac complications of regular hemodialysis therapy. In: Drukker WJ, Parsons FM, Maher F, eds. Replacement of Renal Function by
Dialysis. Martinus Nijhoff, Doerdrecht, 1986:595-607.
8. Hedner T, Hedner J, Andersson O, Prsson B,Pettersson A . ANP : A cardiac hormone and a putative central neurotransmitter. European Heart Journal 1987 ; 8:87¬98.
9. Sonnonberg H . Mechanism of release and renal action of atrial natriuretic factor. Acta Physiol Scand 1990 ; 139:80-87.
10. Bilder GE, Schofield TL, Bleine EH . Release of atrial
natriuretic factor, effects of repetitive stretch and
temperature. Am J Physiol 1986 ; 251:817-821.
11. Lendsome JR, Wilson N, Rankin AJ, Courneya CA . Time course of release of atrial natriuretic peptide in anaesthetized dog. Can J Physiol Pharmacol 1985 ; 64:1017-1022.
12. Ahmad S, Dennis MJ, Lensenum CJL, Kenny MA . Natriuretic effect of DLIS on dog kidney. Clin Physiol
Biochem 1987; 5:1-8.
13. Ahmad S, Kenny M, Scribner BH . Hypertension and a digoxin-like substance in the plasma of dialysis patients: possible marker for a natriuretic hormone.
13
Clin Physiol Biochem 1986 ; 4:210-216.
14. Bisordi JE, Holt S. Digitalis-like immunoreactive substances and extracellular fluid volume status in chronic hemodialysis patients. Am J Kidney Dis 1989; 13:396-403.
15. Gruber KA, Whitaker JM, Buckalew VM. Endogenous digitalis-like substance in plasma of volume-expanded
dogs. Nature 1980 ; 287:743-745.
16. Scribner V, Kolbel F, Stephen J . Digoxin-like immunoreactivity in the serum of rats with cardiac
overload. J Med Cell Cardiol 1981 ; 13:107-110.
17. Dasgupta A, Trejo O. Suppression of total digoxin concentrations by digoxin-like immunoreactive substances in the MEIA digoxin assay. Elimination of negative interference by monitoring free digoxin
concentrations. Am J Clin Pathol 1999 ; 111 : 406-411.
18. Charra B, Calemard E, Ruffet M. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286¬1291.
19. Ritz E, Wiecek A, Rambausek M. Cardiovascular death in patients with end-stage renal failure: strategies for prevention. Nephrol Dial Transplant 1994 ; 9 (Suppl 2): 120-129.
20. Dorhout Mees EJ, Özbaşlı Ç, Akçiçek F: Cardiovascular disturbancesin hemodialysis patients: the importance of volume overload. J Nephrol 1995; 8:71-78.
21. Kinet JP, Soyeur D, Baillant N, Saint-Remy M,
Collignon P, Godon JP. Hemodynamic study of hypotension during hemodialysis. Kidney Int 1982; 21:868-876.
22. Mandelbaum A, Ritz E. Vena cava diameter measurement for estimation of dry weight in hemodialysis patients. Nephrol Dial Transplant 1996 ; 11 (Suppl 2) : 24-27.
23. Ruffmann K, Mandelbaum A, Baumer J. Echocardiographic findings in dialysis patients.
Nephrol Dial Transplant 1990 ; 5:426-43 1.
24. Îkram H, Lynn KL, Bailey RR, Little PJ. Cardiovascular changes in chronic hemodialysis
patients. Kidney Int 1983 ; 24:371-376.
25. Porfrey PS, Hornett JD, Griffiths SM. The clinical
course of left ventricular hypertrophy in dialysis
patient. Nephron 1990 ; 55:114-120.
26. Golf S, Lunde P, Abrahamson AM, Oyri A. Effect of
hydration on cardiac function in patients on chronic
hemodialysis. Br Heart J 1983 ; 49:183-186.
27. Koomans HA, Geers AB, Dorhout Mees EJ. Plasma volume recovery after ultrafiltration in patients with chronic renal failure. Kidney Int 1984; 26:848-854.
28. Litwin SE,Grossmann V. Diastolic dysfunction as a
cause of heart failure. J Am Coll Cardiol 1993;22 (S4):
A49-A55.
14

Thank you for copying data from http://www.arastirmax.com